http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2463451-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efd09c296645384c4e1c770411f7aa01 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2006-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14b5a3f5eed3b4eecf5b383b68dbe6fb |
| publicationDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2463451-T3 |
| titleOfInvention | Detection of soluble adiponectin receptor peptides and use in diagnosis and therapy |
| abstract | A method for predicting a condition, determining the progress of a condition, the onset of a condition, or the effectiveness of treating a condition, said condition being characterized by an adipocyte imbalance and being selected from the group consisting of obesity, resistance to insulin, type II diabetes, metabolic syndrome, dyslipidemia, cardiovascular disease, hypertension, vascular obstruction, type I diabetes, inflammation and arteriosclerosis by detecting the fragmentation of an adiponectin receptor in a subject that comprises the stage of determining the level of at least one soluble fragment of terminal C of the adiponectin receptor in a sample of biological fluid obtained from the subject, wherein the step of determining the level of at least one soluble fragment of terminal C comprises determining the total level of the fragments soluble of the C terminal and wherein said method is to predict said condition and an in Increase in the total level of soluble fragments of the C-terminal relative to a non-diseased adiponectin receptor subject is indicative that said subject has a condition; or wherein the step of determining the level of at least one soluble fragment of terminal C comprises determining the total level of soluble fragments of terminal C and wherein said method is for determining the progress of a condition and an increase in relation to a previous measurement is indicative of a worsening of said condition; or wherein said at least one soluble fragment of the C terminal is 25 to 34 amino acids in length and comprises a peptide with a sequence selected from the group of sequences consisting of SEQ ID NOs: 1, 2, 4 to 10, 23, 24 and 26 to 33 or a sequence with an identity of 80% or greater with it and wherein a smaller amount of said at least one soluble fragment of the C terminal with 25 to 34 amino acids in length with respect to a non-diseased subject of adiponectin receptor is indicative that said subject having a condition or an increase over a previous measurement is indicative of a worsening of said condition; or wherein said at least one soluble fragment of the C terminal is 13 to 24 amino acids in length and comprises a peptide with a sequence selected from the sequence group consisting of SEQ ID NOs: 3, 12 to 22, 25 and 34 a 44 or a sequence with an identity of 80% or greater with it and wherein a greater amount of said at least one soluble fragment of the C terminal with 13 to 24 amino acids in length with respect to a non-diseased subject of the adiponectin receptor is indicative that said subject that has a condition |
| priorityDate | 2005-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 948.